Open questions between immune checkpoint inhibitors and tuberculosis incidence.
作者信息
Wen Ying, Kang Jing
机构信息
Department of Infectious Diseases, The First Affiliated Hospital of China Medical University, Shenyang, China.
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Immunology, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang, China.
出版信息
J Thorac Dis. 2024 Aug 31;16(8):5484-5486. doi: 10.21037/jtd-24-890. Epub 2024 Aug 5.
Abstract
摘要
相似文献
1
Open questions between immune checkpoint inhibitors and tuberculosis incidence.免疫检查点抑制剂与结核病发病率之间的未决问题。
J Thorac Dis. 2024 Aug 31;16(8):5484-5486. doi: 10.21037/jtd-24-890. Epub 2024 Aug 5.
2
Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.接受免疫检查点抑制剂治疗的肺癌患者中活动性肺结核的发病率。
Open Forum Infect Dis. 2020 Apr 9;7(5):ofaa126. doi: 10.1093/ofid/ofaa126. eCollection 2020 May.
3
Cancer immunotherapy with immune checkpoint inhibitors and infections: A particular focus on mycobacterial infections.癌症免疫疗法中的免疫检查点抑制剂与感染：特别关注分枝杆菌感染。
Respir Investig. 2024 May;62(3):339-347. doi: 10.1016/j.resinv.2024.02.002. Epub 2024 Feb 27.
4
Immune checkpoint modulating T cells and NK cells response to Mycobacterium tuberculosis infection.免疫检查点调节 T 细胞和 NK 细胞对结核分枝杆菌感染的反应。
Microbiol Res. 2023 Aug;273:127393. doi: 10.1016/j.micres.2023.127393. Epub 2023 May 3.
5
Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study.肺癌患者接受免疫检查点抑制剂治疗时的序贯干扰素-γ释放试验：一项前瞻性队列研究。
Cancer Immunol Immunother. 2022 Nov;71(11):2757-2764. doi: 10.1007/s00262-022-03198-1. Epub 2022 Apr 16.
6
Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.免疫检查点抑制剂治疗晚期肺癌患者的结核病发病率：一项全国基于人群的队列研究。
Lung Cancer. 2021 Aug;158:107-114. doi: 10.1016/j.lungcan.2021.05.034. Epub 2021 May 31.
7
Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients.免疫检查点抑制剂 (ICIs) 治疗对非小细胞肺癌 (NSCLC) 患者干扰素-γ 释放试验 (IGRA) 及诊断价值的影响。
BMC Pulm Med. 2024 Apr 12;24(1):174. doi: 10.1186/s12890-024-02980-4.
8
Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review.免疫检查点抑制剂联合靶向治疗转移性黑色素瘤的理由：综述。
JAMA Oncol. 2020 Dec 1;6(12):1957-1966. doi: 10.1001/jamaoncol.2020.4401.
9
Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations.免疫检查点抑制剂治疗后癌症患者结核病的再激活：当前证据和临床实践建议。
J Immunother Cancer. 2019 Sep 4;7(1):239. doi: 10.1186/s40425-019-0717-7.
10
Immune checkpoint inhibitors and tuberculosis: an old disease in a new context.免疫检查点抑制剂与结核病：新形势下的老问题。
Lancet Oncol. 2020 Jan;21(1):e55-e65. doi: 10.1016/S1470-2045(19)30674-6.
本文引用的文献
1
A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?关于使用免疫检查点抑制剂引发分枝杆菌感染风险争议的叙述性综述：金发姑娘知道答案吗？
J Thorac Dis. 2024 Feb 29;16(2):1601-1624. doi: 10.21037/jtd-23-1395. Epub 2024 Feb 27.
2
Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.接受免疫检查点抑制剂治疗的患者结核再激活风险增加。
Oncologist. 2024 Apr 4;29(4):e498-e506. doi: 10.1093/oncolo/oyad340.
3
Risk Factors for Pulmonary Tuberculosis in Patients with Lung Cancer: A Retrospective Cohort Study.肺癌患者肺结核的危险因素：一项回顾性队列研究。
J Cancer. 2023 Mar 5;14(4):657-664. doi: 10.7150/jca.81616. eCollection 2023.
4
PD-1 Inhibitor for Disseminated Infection in a Person With HIV.用于治疗HIV感染者播散性感染的PD-1抑制剂
Open Forum Infect Dis. 2022 Dec 28;10(1):ofac700. doi: 10.1093/ofid/ofac700. eCollection 2023 Jan.
5
The Prevalence of Mycobacterium tuberculosis Infection Among Cancer Patients Receiving Chemotherapy in a Tertiary Care Center.某三级医疗中心接受化疗的癌症患者中结核分枝杆菌感染的患病率
Cureus. 2022 Nov 30;14(11):e32068. doi: 10.7759/cureus.32068. eCollection 2022 Nov.
6
Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy.免疫失调相关感染：癌症免疫治疗的一种新出现的并发症。
Thorax. 2022 Mar;77(3):304-311. doi: 10.1136/thoraxjnl-2021-217260. Epub 2021 Oct 4.
7
Organizing pneumonia-presenting acute respiratory distress syndrome because of paradoxical tuberculosis-immune reconstitution disease?
AIDS. 2021 Feb 2;35(2):351-354. doi: 10.1097/QAD.0000000000002752.
8
Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.免疫检查点抑制后结核病再激活的影响
Am J Respir Crit Care Med. 2018 Dec 1;198(11):1451-1453. doi: 10.1164/rccm.201807-1250LE.
9
Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literature.HIV 血清阳性结核病病例在开始抗逆转录病毒治疗后出现黄疸的临床病理相关性：文献综述
BMC Infect Dis. 2012 Oct 14;12:257. doi: 10.1186/1471-2334-12-257.
10
Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis.程序性死亡受体-1（PD-1）缺陷型小鼠对结核分枝杆菌感染极为敏感。
Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13402-7. doi: 10.1073/pnas.1007394107. Epub 2010 Jul 12.
Zotero 插件